113 related articles for article (PubMed ID: 22921070)
1. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity.
Echalier A; Cot E; Camasses A; Hodimont E; Hoh F; Jay P; Sheinerman F; Krasinska L; Fisher D
Chem Biol; 2012 Aug; 19(8):1028-40. PubMed ID: 22921070
[TBL] [Abstract][Full Text] [Related]
2. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
3. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
4. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
5. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
6. Truncation and optimisation of peptide inhibitors of cyclin-dependent kinase 2-cyclin a through structure-guided design.
Kontopidis G; Andrews MJ; McInnes C; Plater A; Innes L; Renachowski S; Cowan A; Fischer PM
ChemMedChem; 2009 Jul; 4(7):1120-8. PubMed ID: 19472269
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel class of 2-aminopyrimidines as CDK1 and CDK2 inhibitors.
Lee J; Kim KH; Jeong S
Bioorg Med Chem Lett; 2011 Jul; 21(14):4203-5. PubMed ID: 21684737
[TBL] [Abstract][Full Text] [Related]
8. Selective chemical inhibition as a tool to study Cdk1 and Cdk2 functions in the cell cycle.
Krasinska L; Cot E; Fisher D
Cell Cycle; 2008 Jun; 7(12):1702-8. PubMed ID: 18583935
[TBL] [Abstract][Full Text] [Related]
9. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach.
Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C
J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593
[TBL] [Abstract][Full Text] [Related]
10. Cdk1 and Cdk2 activity levels determine the efficiency of replication origin firing in Xenopus.
Krasinska L; Besnard E; Cot E; Dohet C; Méchali M; Lemaitre JM; Fisher D
EMBO J; 2008 Mar; 27(5):758-69. PubMed ID: 18256689
[TBL] [Abstract][Full Text] [Related]
11. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors.
Vulpetti A; Casale E; Roletto F; Amici R; Villa M; Pevarello P
J Mol Graph Model; 2006 Mar; 24(5):341-8. PubMed ID: 16260160
[TBL] [Abstract][Full Text] [Related]
12. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
13. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
14. Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D; Dutruc-Rosset G; Tiraboschi G; Dreyer MK; Maignan S; Chevalier A; Halley F; Bertrand P; Burgevin MC; Quarteronet D; Rooney T
Bioorg Med Chem Lett; 2010 Mar; 20(6):1985-9. PubMed ID: 20167481
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
16. Type II Inhibitors Targeting CDK2.
Alexander LT; Möbitz H; Drueckes P; Savitsky P; Fedorov O; Elkins JM; Deane CM; Cowan-Jacob SW; Knapp S
ACS Chem Biol; 2015 Sep; 10(9):2116-25. PubMed ID: 26158339
[TBL] [Abstract][Full Text] [Related]
17. Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.
Pratt DJ; Bentley J; Jewsbury P; Boyle FT; Endicott JA; Noble ME
J Med Chem; 2006 Sep; 49(18):5470-7. PubMed ID: 16942020
[TBL] [Abstract][Full Text] [Related]
18. Characterization of murine gammaherpesvirus 68 v-cyclin interactions with cellular cdks.
Upton JW; van Dyk LF; Speck SH
Virology; 2005 Oct; 341(2):271-83. PubMed ID: 16102793
[TBL] [Abstract][Full Text] [Related]
19. Homology model of the CDK1/cyclin B complex.
McGrath CF; Pattabiraman N; Kellogg GE; Lemcke T; Kunick C; Sausville EA; Zaharevitz DW; Gussio R
J Biomol Struct Dyn; 2005 Apr; 22(5):493-502. PubMed ID: 15702922
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex.
Russo AA; Jeffrey PD; Patten AK; Massagué J; Pavletich NP
Nature; 1996 Jul; 382(6589):325-31. PubMed ID: 8684460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
